DelveInsight’s 'Complement Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline complement inhibitors in various stages of clinical development, major ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Two recently discovered viruses of the myxovirus family termed hemadsorption Types 1 and 2 have been studied as causes of respiratory diseases in children under ten years old. 1,2 ‡ One or the other ...
SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback